Sammy Dorf was named Chairman of the Board of Onconetix, Inc., effective April 23, 2026. As of November 6, 2026, Onconetix, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 24, 2026, naming 2 appointments (Form 8-K, April 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Onconetix, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Onconetix, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-24. It names 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Onconetix, Inc. files it.
Also on the record for Onconetix, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by Keystone Capital Partners, LLC | 6.32% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by Keystone Capital Partners, LLC | 6.1% of the class | 5%+ stakes | Source |
| October 7, 2025 | Form D, private offering | $12.98M sold | Form D page | Source |
| July 16, 2025 | Stake report, Schedule 13D/A, by Altos Venture AG | 35.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Onconetix, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Onconetix, Inc. and the records around it.
Onconetix, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Watch Onconetix, Inc.
Get an email when Onconetix, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Onconetix, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Onconetix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Onconetix, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-24 | In | Chairman of the Board | 2026-04-23 | 8-K, 2026-04-24 | |
| 2026-04-24 | In | Director | 2026-04-23 | 8-K, 2026-04-24 |
Who leads Onconetix, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Josh Epstein, appointed, effective 2026-04-23 (filed 2026-04-24).
- Chairman of the Board: Sammy Dorf, appointed, effective 2026-04-23 (filed 2026-04-24).
New leaders reset buying decisions — get the Full Report on Onconetix, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chairman of the Board at Onconetix, Inc., with the record behind each one.
Find candidates like Chairman of the Board at Onconetix, Inc.Every change, in the filing's words
Appointed: Sammy Dorf, Chairman of the Board, effective 2026-04-23
Effective on April 23, 2026, the Board has appointed Sammy Dorf, an existing member of the Board, as Chairman of the Board.
Appointed: Josh Epstein, Director, effective 2026-04-23
Effective as of April 23, 2026, the Board elected Josh Epstein to serve as a member of the Board and a member of the Audit Committee, Compensation Committee and as the chair of the Nominating and Corporate Governance Committee.
- Resignation of Andrew Oakley and Thomas Meier as Directors; Elections of Sammy Dorf as Chairman of the Board Effective on April 20, 2026, Andrew Oakley and Thomas Meier notified the Board of Directors (the "Board") of Onconetix, Inc, a Delaware corporation (the "Company"), of their resignation from the Board.
- As a result of their resignation from the Board and effective as of the date mentioned herein, Mr. Oakley has also resigned from his position as Chairman of the Board and his service on the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee, and Mr. Meier has also resigned from his service on the Compensation Committee.
- Mr. Oakley's and Mr. Meier's departures from the Board were not the result of any disagreement with management or the Board on any matter relating to the Company's operations, policies or practices.
- In connection with Mr. Dorf's election as Chairman, the Compensation Committee of the Board has agreed to compensate Mr. Dorf $20,000 per year, payable on a quarterly basis, commencing on the date of his election.
- Mr. Epstein will be a Class II director and will serve for a term expiring at the Company's 2026 annual meeting of stockholders.
Tools for this story
Each opens in a new tab, filled in for Onconetix, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.